Full history for every metric is available with a Kvantra account
Pherecydes Pharma S.A. (ALPHE.PA)
Key financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 2 | 2 | 2 | 3 |
| Operating profit | €m | -7 | |||||
| Net profit | €m | -2 | -2 | -2 | -3 | -3 | -5 |
| EPS reported | € | -0.75 | |||||
| Operating cashflow per share | € | 0.00 | |||||
| Capex per share | € | 0.00 | |||||
| FCF per share | € | 0.00 | |||||
| Free cash flow | €m | - | |||||
| Net debt | €m | 2 | |||||
| Book value equity | €m | 8 | |||||
| Book value per share | € | 1.04 | |||||
| Number of shares | m | 7.2 | |||||
| DPS (TTM paid) | € | 0.00 |
Financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 2.00 | |||||
| P/S LTM | x | 4.77 | |||||
| P/FCF LTM | x | 0.00 | |||||
| EV/EBITDA LTM | x | -2.65 | |||||
| EV/Sales LTM | x | 5.25 | |||||
| Earnings Yield LTM | % | -35.66% | |||||
| FCF Yield | % | 0.00% | |||||
| Quality | |||||||
| ROE | % | -71.33% | |||||
| ROIC | % | -50.18% | |||||
| Operating margin | % | -212.03% | |||||
| Gross margin | % | -2.95% | |||||
| FCF/Sales | % | 0.00% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +47.29% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | - | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | - | |||||
| Net Debt/EBITDA | x | -0.24 | |||||
| EBIT/Net interest | x | -103.70 | |||||
| Net debt/market cap | % | 9.99% | |||||
| Net debt/Equity | x | 0.20 | |||||
| Gross debt/equity | x | 0.34 | |||||
Company overview
Pherecydes Pharma S.A. focuses on developing antimicrobial treatments by leveraging bacteriophage viruses, also known as phages. The company's pipeline includes a range of therapeutic options: phages engineered to combat Staphylococcus aureus in bone/joint and diabetic foot ulcer infections; phages targeting Pseudomonas aeruginosa for complicated urinary tract infections; and phages designed to address Escherichia coli in respiratory tract infections. The firm was founded in 2006 and is headquartered in Romainville, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pherecydes Pharma S.A. (ALPHE.PA)
Pherecydes Pharma S.A. focuses on developing antimicrobial treatments by leveraging bacteriophage viruses, also known as phages. The company's pipeline includes a range of therapeutic options: phages engineered to combat Staphylococcus aureus in bone/joint and diabetic foot ulcer infections; phages targeting Pseudomonas aeruginosa for complicated urinary tract infections; and phages designed to address Escherichia coli in respiratory tract infections. The firm was founded in 2006 and is headquartered in Romainville, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free